201 related articles for article (PubMed ID: 33052634)
1. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
Davydova YO; Parovichnikova EN; Galtseva IV; Kokhno AV; Dvirnyk VN; Kovrigina AM; Obukhova TN; Kapranov NM; Nikiforova KA; Glinkina SA; Troitskaya VV; Mikhailova EA; Fidarova ZT; Moiseeva TN; Lukina EA; Tsvetaeva NV; Nikulina OF; Kuzmina LA; Savchenko VG
Cytometry B Clin Cytom; 2021 May; 100(3):312-321. PubMed ID: 33052634
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of the lymphoid screening tube supplemented with CD34 for Ogata score calculation in patients with peripheral cytopenia.
Muyldermans A; Florin L; Devos H; Cauwelier B; Emmerechts J
Hematology; 2019 Dec; 24(1):166-172. PubMed ID: 30334700
[TBL] [Abstract][Full Text] [Related]
3. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
[TBL] [Abstract][Full Text] [Related]
4. Dysplasia and PNH-type cells in bone marrow aspirates of myelodysplastic syndromes.
Westers TM; Alhan C; Visser-Wisselaar HA; Chitu DA; van de Loosdrecht AA
Cytometry B Clin Cytom; 2023 Mar; 104(2):162-172. PubMed ID: 34806840
[TBL] [Abstract][Full Text] [Related]
5. Comparison of High Sensitivity and Conventional Flow Cytometry for Diagnosing Overt Paroxysmal Nocturnal Hemoglobinuria and Detecting Minor Paroxysmal Nocturnal Hemoglobinuria Clones.
Park SH; Jeong J; Lee SH; Yoo DW; Choi Y; Jo JC; Lim JH
Ann Lab Med; 2019 Mar; 39(2):150-157. PubMed ID: 30430777
[TBL] [Abstract][Full Text] [Related]
6. Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.
Wong SA; Dalal BI; Leitch HA
Curr Oncol; 2018 Oct; 25(5):e391-e397. PubMed ID: 30464689
[TBL] [Abstract][Full Text] [Related]
7. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
8. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.
Raza A; Ravandi F; Rastogi A; Bubis J; Lim SH; Weitz I; Castro-Malaspina H; Galili N; Jawde RA; Illingworth A
Cytometry B Clin Cytom; 2014 May; 86(3):175-82. PubMed ID: 24227693
[TBL] [Abstract][Full Text] [Related]
9. Standardized high-sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria in children with acquired bone marrow failure disorders: A single center US study.
Donohue RE; Marcogliese AN; Sasa GS; Elghetany MT; Redkar AA; Bertuch AA; Curry CV
Cytometry B Clin Cytom; 2018 Jul; 94(4):699-704. PubMed ID: 28574201
[TBL] [Abstract][Full Text] [Related]
10. Analysis of abnormal clones by the fluorescent aerolysin method in paroxysmal nocturnal haemoglobinuria and other marrow disorders.
Agarwal R; Chapple P; Brown M; Szer J; Juneja S
Int J Lab Hematol; 2015 Feb; 37(1):14-21. PubMed ID: 24702736
[TBL] [Abstract][Full Text] [Related]
11. A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.
Mannelli F; Bencini S; Peruzzi B; Cutini I; Sanna A; Benelli M; Magi A; Gianfaldoni G; Rotunno G; Carrai V; Gelli AM; Valle V; Santini V; Notaro R; Luzzatto L; Bosi A
Cytometry B Clin Cytom; 2013 Mar; 84(2):71-81. PubMed ID: 23281097
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications.
Morado M; Freire Sandes A; Colado E; Subirá D; Isusi P; Soledad Noya M; Belén Vidriales M; Sempere A; Ángel Díaz J; Minguela A; Álvarez B; Serrano C; Caballero T; Rey M; Pérez Corral A; Cristina Fernández Jiménez M; Magro E; Lemes A; Benavente C; Bañas H; Merino J; Castejon C; Gutierrez O; Rabasa P; Vescosi Gonçalves M; Perez-Andres M; Orfao A;
Cytometry B Clin Cytom; 2017 Sep; 92(5):361-370. PubMed ID: 27598686
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
[TBL] [Abstract][Full Text] [Related]
14. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
[TBL] [Abstract][Full Text] [Related]
15. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
[TBL] [Abstract][Full Text] [Related]
16. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
[TBL] [Abstract][Full Text] [Related]
17. Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones).
Chen Z; Ok CY; Wang W; Goswami M; Tang G; Routbort M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2020 Jan; 98(1):36-42. PubMed ID: 31211490
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
20. Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats.
Wang SA; Pozdnyakova O; Jorgensen JL; Medeiros LJ; Stachurski D; Anderson M; Raza A; Woda BA
Haematologica; 2009 Jan; 94(1):29-37. PubMed ID: 19001281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
